Aeterna Zentaris Inc.
AEZS.TO
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.51M
Close$
Share Statistics
| Market cap | $17.51 Million |
|---|---|
| Enterprise Value | $-1,794,133.00 |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -65.14% |
|---|---|
| Return on Assets | -34.14% |
| Return on Invested Capital | -51.91% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -0.73 |
| Enterprise Value to EBIT | 0.09 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -4.74 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aeterna Zentaris Inc.
28 employees
CEO: Klaus Paulini Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved ora...